The cervical solution marks the completion of the NuVasive Reline fixation portfolio for complex deformity from occiput to sacrum
"Reline Cervical completes the foundational three strategic pillars of
As cervical spine procedures comprise an approximately $2.6 billion subsegment of the global spine market, the introduction of Reline Cervical will allow the Company's
"The Reline Cervical design is best-in-class. I'm impressed by the screw range, great connector options, and the full junctional offering, helping me address the varying complex deformity cases I see in my practice," said Steven Ludwig, M.D., orthopedic spine surgeon at the
The expansion of the
NuVasive will feature its
- NuVasive Innovation Event: On
November 16, join NuVasivevirtually to hear Company leadership and surgeon partners discuss all comprehensive procedural portfolios—X360, C360, thoracolumbar posterior, posterior fixation, pediatrics, and the enabling technologies within Pulse. Hear from surgeons on the Reline Cervical system and how it has already made an impact on their practices.
- 50th Cervical Spine Research Society Annual Meeting: From
November 16 to 19, visit NuVasive at booth #105/204 to see the full C360portfolio—Reline Cervical, the Simplify® Cervical Disc, the NuVasiveanterior cervical plate system, cervical Advanced Materials Science® interbody implants, and Pulse.
Reline Cervical is available in the
NuVasive cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company's surgical products and procedures by spine surgeons and hospitals, development and acceptance of new products or product enhancements, clinical and statistical verification of the benefits achieved via the use of NuVasive's products, the Company's ability to adequately manage inventory as it continues to release new products, its ability to recruit and retain management and key personnel, and the other risks and uncertainties described in NuVasive's news releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.
View original content to download multimedia:https://www.prnewswire.com/news-releases/nuvasive-launches-reline-cervical-for-posterior-cervical-fusion-as-part-of-the-c360-portfolio-301635108.html
Investor contact: Juliet C. Cunningham, NuVasive, Inc., 858-210-2129, email@example.com; or Media contact: Melanie Ordoñez, NuVasive, Inc., 858-722-3899, firstname.lastname@example.org